Q-omics provides the consensus-scored UBE2A profile across patient tissues and cancer cell-line models. UBE2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, UBE2A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, UBE2A protein abundance shows 25,534 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where UBE2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2A survival associations across molecular data types. UBE2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2A RNA expression–survival associations across cancer types. High UBE2A expression shows unfavorable associations in MESO, KIRP, UVM, BRCA, HNSC and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for UBE2A RNA expression.
This table summarizes UBE2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBE2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2A shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, THCA and STAD. The HNSC box plot shows higher UBE2A RNA expression in tumor versus normal tissue (log2 FC = +1.003, t-test p < 0.001).
This table shows molecular features associated with UBE2A in patient tissues and cancer cell lines. In patient samples, UBE2A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and STOMACH.
